Tenaya Therapeutics (TNYA) Announces Updates on TN-201 Gene Therapy Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Leerink Partners Reiterates Outperform Rating on Tenaya Therapeutics Inc (TNYA)
October 18, 2024 5:47 AM EDTLeerink Partners analyst Mani Foroohar reiterated an Outperform rating and $8.00 price target on Tenaya Therapeutics Inc (NASDAQ: TNYA)
The analyst comments "Bottom Line: After the close, TNYA shared updates on its Phase 1b/2 MyPEAK-1 trial of TN-201 in MYBPC3-associated hypertrophic cardiomyopathy (MYBPC3-HCM). Cohort 1 (3E13 vg/kg, n=3 with first patient dosed in October 2023) showed a safety/tolerability profile... More
